REGENXBIO, Inc. (RGNX)
6.76
+0.79
(+13.23%)
USD |
NASDAQ |
May 21, 16:00
6.76
0.00 (0.00%)
After-Hours: 19:59
REGENXBIO Research and Development Expense (TTM) : 217.03M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Sarepta Therapeutics, Inc. | 896.74M |
| Ocugen, Inc. | 39.60M |
| Replimune Group, Inc. | 222.70M |
| AbbVie, Inc. | 9.501B |
| Krystal Biotech, Inc. | 54.64M |